Calliditas Therapeutics: Reiterating our Valuation

Research Note

2021-02-04

08:56

Redeye reiterates its positive stance on Calliditas following the termination of the proposed global offering. While the situation caused uncertainty among investors, we also recognize that nothing fundamental in the case has changed. We reiterate our Base case of SEK 250 per share.

LS

Ludvig Svensson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.